title: Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
abstract: BACKGROUND
  The aim of this study was to assess feasibility and efficacy of weekly concomitant boost accelerated postoperative radiation therapy (PORT) with concomitant chemotherapy (CT) in patients with locally advanced head and neck cancer (LAHNC).
  
  
  METHODS
  Conformal or intensity-modulated 66-Gy RT was performed in 5.5 weeks in 40 patients. Cisplatin was given at days 1, 22, and 43. Median follow-up was 36 months.
  
  
  CONCLUSIONS
  Grade 3 mucositis, dysphagia, and erythema was observed in ten (25%), nine (23%), and six (13%) patients, respectively. Grade 3 or more anemia was observed in two (6%) patients, and leukopenia in five (13%) patients. No grade 3 or 4 thrombocytopenia was observed. Grade 3 nephrotoxicity was observed in one patient (3%). No treatment-related mortality was observed. Grade 2 or more xerostomia and edema were observed in ten (25%) and one (3%) patient, respectively. Locoregional relapse occurred in eight patients, and seven patients developed distant metastases. Median time to locoregional relapse was 6 months. Three-year overall, disease-free survival, and locoregional control rates were 63%, 62%, and 81%, respectively. Multivariate analysis revealed that the only prognostic factor was nodal status.
  
  
  CONCLUSIONS
  Reducing overall treatment time using accelerated PORT/CT by weekly concomitant boost (six fractions per week) combined with concomitant cisplatin CT is easily feasible with acceptable morbidity.
authors.affiliation: Department of Radiation Oncology, University Hospital Center, University of Lausanne, Lausanne, Switzerland.
authors.forename: Berrin
authors.initials: B
authors.lastname: Pehlivan
authors.forename: Francois
authors.initials: F
authors.lastname: Luthi
authors.forename: Oscar
authors.initials: O
authors.lastname: Matzinger
authors.forename: Michael
authors.initials: M
authors.lastname: Betz
authors.forename: Daniela
authors.initials: D
authors.lastname: Dragusanu
authors.forename: Shelley
authors.initials: S
authors.lastname: Bulling
authors.forename: Luc
authors.initials: L
authors.lastname: Bron
authors.forename: Philippe
authors.initials: P
authors.lastname: Pasche
authors.forename: Walter
authors.initials: W
authors.lastname: Seelentag
authors.forename: René O
authors.initials: RO
authors.lastname: Mirimanoff
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Zouhair
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D005240:Feasibility Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D020266:Radiotherapy, Conformal; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin